{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:25:26Z","timestamp":1792265126496,"version":"4.4.0"},"reference-count":152,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sexual Medicine Reviews"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1002\/smrj.3","type":"journal-article","created":{"date-parts":[[2013,4,30]],"date-time":"2013-04-30T13:49:35Z","timestamp":1367329775000},"page":"24-41","source":"Crossref","is-referenced-by-count":53,"title":["Side Effects of 5\u2010Alpha Reductase Inhibitors: A Comprehensive Review"],"prefix":"10.1093","volume":"1","author":[{"given":"Landon","family":"Trost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore R.","family":"Saitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne J.G.","family":"Hellstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1002\/smrj.3_bb0010","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0306-4530(98)00071-7","article-title":"Neurosteroids: A novel function of the brain","volume":"23","author":"Baulieu","year":"1998","journal-title":"Psychoneuroendocrinology"},{"key":"10.1002\/smrj.3_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1447-073x.2005.00098.x","article-title":"Topography and function of androgen\u2010metabolizing enzymes in the central nervous system","volume":"80","author":"Tsuruo","year":"2005","journal-title":"Anat Sci Int"},{"key":"10.1002\/smrj.3_bb0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev.bi.63.070194.000325","article-title":"Steroid 5 alpha\u2010reductase: Two genes\/two enzymes","volume":"63","author":"Russell","year":"1994","journal-title":"Annu Rev Biochem"},{"key":"10.1002\/smrj.3_bb0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1349-7006.2007.00656.x","article-title":"Novel 5 alpha\u2010steroid reductase (SRD5A3, type\u20103) is overexpressed in hormone\u2010refractory prostate cancer","volume":"99","author":"Uemura","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1002\/smrj.3_bb0030","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/(SICI)1097-4695(19990915)40:4<471::AID-NEU5>3.0.CO;2-P","article-title":"Steroid metabolism and effects in central and peripheral glial cells","volume":"40","author":"Melcangi","year":"1999","journal-title":"J Neurobiol"},{"key":"10.1002\/smrj.3_bb0035","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1073\/pnas.87.10.3640","article-title":"Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha\u2010reductases","volume":"87","author":"Andersson","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1002\/smrj.3_bb0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0090-4295(01)01347-4","article-title":"5alpha\u2010reductase inhibitors: What role should they play?","volume":"58","author":"Kaplan","year":"2001","journal-title":"Urology"},{"key":"10.1002\/smrj.3_bb0045","first-page":"1373","article-title":"MK\u2010386, an inhibitor of 5alpha\u2010reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen","volume":"82","author":"Schwartz","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1002\/smrj.3_bb0050","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1172\/JCI116665","article-title":"Tissue distribution and ontogeny of steroid 5 alpha\u2010reductase isozyme expression","volume":"92","author":"Thigpen","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1002\/smrj.3_bb0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s004410100464","article-title":"Expression of the androgen receptor and 5 alpha\u2010reductase type 2 in the developing human fetal penis and urethra","volume":"307","author":"Kim","year":"2002","journal-title":"Cell Tissue Res"},{"key":"10.1002\/smrj.3_bb0060","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/pros.21318","article-title":"5alpha\u2010reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progression","volume":"71","author":"Godoy","year":"2011","journal-title":"Prostate"},{"key":"10.1002\/smrj.3_bb0065","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJM199802263380901","article-title":"The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long\u2010Term Efficacy and Safety Study Group","volume":"338","author":"McConnell","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1002\/smrj.3_bb0070","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","article-title":"Efficacy and safety of a dual inhibitor of 5\u2010alpha\u2010reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia","volume":"60","author":"Roehrborn","year":"2002","journal-title":"Urology"},{"key":"10.1002\/smrj.3_bb0075","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0090-4295(98)00567-6","article-title":"Long\u2010term effects of finasteride on prostate tissue composition","volume":"53","author":"Marks","year":"1999","journal-title":"Urology"},{"key":"10.1002\/smrj.3_bb0080","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.eururo.2004.05.008","article-title":"Efficacy and safety of long\u2010term treatment with the dual 5 alpha\u2010reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia","volume":"46","author":"Debruyne","year":"2004","journal-title":"Eur Urol"},{"key":"10.1002\/smrj.3_bb0085","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0190-9622(98)70007-6","article-title":"Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group","volume":"39","author":"Kaufman","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1002\/smrj.3_bb0090","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0190-9622(99)70081-2","article-title":"Finasteride in the treatment of men with frontal male pattern hair loss","volume":"40","author":"Leyden","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1002\/smrj.3_bb0095","first-page":"150","article-title":"Efficacy and tolerability of finasteride 1\u2009mg in men aged 41 to 60 years with male pattern hair loss","volume":"13","author":"Whiting","year":"2003","journal-title":"Eur J Dermatol"},{"key":"10.1002\/smrj.3_bb0100","first-page":"310","article-title":"Update on urology\u2013prostate cancer. 1\u2013The molecular basis for prostatic cancer: How it may influence treatment choice","volume":"21","author":"Newling","year":"1995","journal-title":"Eur J Surg Oncol"},{"key":"10.1002\/smrj.3_bb0105","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/j.1743-6109.2011.02368.x","article-title":"An old problem with a new cause\u20105 alpha reductase inhibitors and persistent sexual dysfunction","volume":"8","author":"Goldstein","year":"2011","journal-title":"J Sex Med"},{"key":"10.1002\/smrj.3_bb0110","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.4088\/JCP.12m07887","article-title":"Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects","volume":"73","author":"Irwig","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/smrj.3_bb0115","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1111\/j.1743-6109.2008.01001.x","article-title":"5\u2010alpha reductase inhibitors and erectile dysfunction: The connection","volume":"5","author":"Erdemir","year":"2008","journal-title":"J Sex Med"},{"key":"10.1002\/smrj.3_bb0120","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1743-6109.2010.02157.x","article-title":"Adverse side effects of 5alpha\u2010reductase inhibitors therapy: Persistent diminished libido and erectile dysfunction and depression in a subset of patients","volume":"8","author":"Traish","year":"2011","journal-title":"J Sex Med"},{"key":"10.1002\/smrj.3_bb0125","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/j.1743-6109.2011.02255.x","article-title":"Persistent sexual side effects of finasteride for male pattern hair loss","volume":"8","author":"Irwig","year":"2011","journal-title":"J Sex Med"},{"key":"10.1002\/smrj.3_bb0130","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1111\/j.1743-6109.2012.02846.x","article-title":"Persistent sexual side effects of finasteride: Could they be permanent?","volume":"9","author":"Irwig","year":"2012","journal-title":"J Sex Med"},{"key":"10.1002\/smrj.3_bb0135","doi-asserted-by":"crossref","first-page":"19786","DOI":"10.1074\/jbc.C109.016931","article-title":"Inhibition of human steroid 5beta\u2010reductase (AKR1D1) by finasteride and structure of the enzyme\u2010inhibitor complex","volume":"284","author":"Drury","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1002\/smrj.3_bb0140","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0302-2838(03)00198-2","article-title":"Safety and tolerability of the dual 5alpha\u2010reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia","volume":"44","author":"Andriole","year":"2003","journal-title":"Eur Urol"},{"key":"10.1002\/smrj.3_bb0145","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00345-002-0248-5","article-title":"Dihydrotestosterone and the concept of 5alpha\u2010reductase inhibition in human benign prostatic hyperplasia","volume":"19","author":"Bartsch","year":"2002","journal-title":"World J Urol"},{"key":"10.1002\/smrj.3_bb0150","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000020181","article-title":"Dihydrotestosterone and the concept of 5alpha\u2010reductase inhibition in human benign prostatic hyperplasia","volume":"37","author":"Bartsch","year":"2000","journal-title":"Eur Urol"},{"key":"10.1002\/smrj.3_bb0155","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0039-128X(98)00005-1","article-title":"Effects of the 5 alpha\u2010reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: A prospective clinical study","volume":"63","author":"Uygur","year":"1998","journal-title":"Steroids"},{"key":"10.1002\/smrj.3_bb0160","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1464-410X.2011.10195.x","article-title":"Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: The Enlarged Prostate International Comparator Study (EPICS)","volume":"108","author":"Nickel","year":"2011","journal-title":"BJU Int"},{"key":"10.1002\/smrj.3_bb0165","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1002\/smrj.3_bb0170","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.juro.2007.09.084","article-title":"The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2\u2010year results from the CombAT study","volume":"179","author":"Roehrborn","year":"2008","journal-title":"J Urol"},{"key":"10.1002\/smrj.3_bb0175","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.juro.2008.01.145","article-title":"The effect of 5alpha\u2010reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men","volume":"179","author":"Amory","year":"2008","journal-title":"J Urol"},{"key":"10.1002\/smrj.3_bb0180","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1210\/jc.2006-2203","article-title":"The effect of 5alpha\u2010reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men","volume":"92","author":"Amory","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1002\/smrj.3_bb0185","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1111\/j.1743-6109.2007.00563.x","article-title":"Finasteride 5\u2009mg and sexual side effects: How many of these are related to a nocebo phenomenon?","volume":"4","author":"Mondaini","year":"2007","journal-title":"J Sex Med"},{"key":"10.1002\/smrj.3_bb0190","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/jc.2003-030330","article-title":"Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha\u2010reductase inhibitor","volume":"89","author":"Clark","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1002\/smrj.3_bb0195","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.urology.2004.01.001","article-title":"Efficacy and safety of dutasteride in the four\u2010year treatment of men with benign prostatic hyperplasia","volume":"63","author":"Roehrborn","year":"2004","journal-title":"Urology"},{"key":"10.1002\/smrj.3_bb0200","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0090-4295(02)02114-3","article-title":"Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial","volume":"61","author":"Kirby","year":"2003","journal-title":"Urology"},{"key":"10.1002\/smrj.3_bb0205","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0090-4295(02)02548-7","article-title":"Long\u2010term 6\u2010year experience with finasteride in patients with benign prostatic hyperplasia","volume":"61","author":"Lowe","year":"2003","journal-title":"Urology"},{"key":"10.1002\/smrj.3_bb0210","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long\u2010term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1002\/smrj.3_bb0215","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1002\/smrj.3_bb0220","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0090-4295(02)02401-9","article-title":"Incidence and severity of sexual adverse experiences in finasteride and placebo\u2010treated men with benign prostatic hyperplasia","volume":"61","author":"Wessells","year":"2003","journal-title":"Urology"},{"key":"10.1002\/smrj.3_bb0225","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S0090-4295(98)00666-9","article-title":"Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group","volume":"53","author":"Hudson","year":"1999","journal-title":"Urology"},{"key":"10.1002\/smrj.3_bb0230","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0090-4295(98)00094-6","article-title":"Long\u2010term effects of finasteride in patients with benign prostatic hyperplasia: A double\u2010blind, placebo\u2010controlled, multicenter study. PROWESS Study Group","volume":"51","author":"Marberger","year":"1998","journal-title":"Urology"},{"key":"10.1002\/smrj.3_bb0235","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0149-2918(97)80113-0","article-title":"Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: A primary care study. Primary Care Investigator Study Group","volume":"19","author":"Tenover","year":"1997","journal-title":"Clin Ther"},{"key":"10.1002\/smrj.3_bb0240","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199608223350801","article-title":"The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group","volume":"335","author":"Lepor","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1002\/smrj.3_bb0245","first-page":"1251","article-title":"Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2\u2010year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study","volume":"155","author":"Nickel","year":"1996","journal-title":"CMAJ"},{"key":"10.1002\/smrj.3_bb0250","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0149-2918(95)80073-5","article-title":"Efficacy, tolerability, and effect on health\u2010related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: A community based study. CUSP Investigators. Community based study of Proscar","volume":"17","author":"Byrnes","year":"1995","journal-title":"Clin Ther"},{"key":"10.1002\/smrj.3_bb0255","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/0090-4295(94)90068-X","article-title":"Three\u2010year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia","volume":"43","author":"Stoner","year":"1994","journal-title":"Urology"},{"key":"10.1002\/smrj.3_bb0260","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199210223271701","article-title":"The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group","volume":"327","author":"Gormley","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1002\/smrj.3_bb0265","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/00365590600642010","article-title":"Relationships between lower urinary tract symptoms, the bother they induce and erectile dysfunction","volume":"40","author":"Stroberg","year":"2006","journal-title":"Scand J Urol Nephrol"},{"key":"10.1002\/smrj.3_bb0270","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/ijcp.12044","article-title":"Coexisting lower urinary tract symptoms and erectile dysfunction: A systematic review of epidemiological data","volume":"67","author":"Seftel","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1002\/smrj.3_bb0275","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1464-410X.2011.10846.x","article-title":"Sexual function with localized prostate cancer: Active surveillance vs radical therapy","volume":"110","author":"van den Bergh","year":"2012","journal-title":"BJU Int"},{"key":"10.1002\/smrj.3_bb0280","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1742-1241.2012.03010.x","volume":"66","author":"Kaplan","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1002\/smrj.3_bb0285","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.140.7.857","article-title":"Evaluation of sexual function with an International Index of Erectile Function in subjects taking finasteride for androgenetic alopecia","volume":"140","author":"Tosti","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1002\/smrj.3_bb0290","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1468-3083.2001.00315.x","article-title":"Evaluation of sexual function in subjects taking finasteride for the treatment of androgenetic alopecia","volume":"15","author":"Tosti","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1002\/smrj.3_bb0295","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1111\/j.1743-6109.2011.02425.x","article-title":"The effects of chronic 5\u2010alpha\u2010reductase inhibitor (dutasteride) treatment on rat erectile function","volume":"8","author":"Pinsky","year":"2011","journal-title":"J Sex Med"},{"key":"10.1002\/smrj.3_bb0300","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/j.1743-6109.2012.02759.x","article-title":"Incomplete recovery of erectile function in rat after discontinuation of dual 5\u2010alpha reductase inhibitor therapy","volume":"9","author":"Oztekin","year":"2012","journal-title":"J Sex Med"},{"key":"10.1002\/smrj.3_bb0305","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/j.1743-6109.2012.02661.x","article-title":"Effects of oral finasteride on erectile function in a rat model","volume":"9","author":"Zhang","year":"2012","journal-title":"J Sex Med"},{"key":"10.1002\/smrj.3_bb0310","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1464-410X.1996.00091.x","article-title":"The safety of finasteride used in benign prostatic hypertrophy: A non\u2010interventional observational cohort study in 14,772 patients","volume":"78","author":"Wilton","year":"1996","journal-title":"Br J Urol"},{"key":"10.1002\/smrj.3_bb0315","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1097\/01.ju.0000140957.31325.7f","article-title":"Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia","volume":"172","author":"Watson","year":"2004","journal-title":"J Urol"},{"key":"10.1002\/smrj.3_bb0320","first-page":"77","article-title":"Erectile function in elderly: Role of androgens","volume":"26","author":"Foresta","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"10.1002\/smrj.3_bb0325","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1210\/jcem.87.4.8138","article-title":"The effects of transdermal dihydrotestosterone in the aging male: A prospective, randomized, double blind study","volume":"87","author":"Kunelius","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1002\/smrj.3_bb0330","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1054\/bjoc.1999.0916","article-title":"Prostate cancer treated by anti\u2010androgens: Is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer","volume":"82","author":"Schroder","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1002\/smrj.3_bb0335","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1464-410X.2004.04763.x","article-title":"Quality of life compared during pharmacological treatments and clinical monitoring for non\u2010localized prostate cancer: A randomized controlled trial","volume":"93","author":"Green","year":"2004","journal-title":"BJU Int"},{"key":"10.1002\/smrj.3_bb0340","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000072488","article-title":"Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group","volume":"65","author":"Calais da Silva","year":"2003","journal-title":"Oncology"},{"key":"10.1002\/smrj.3_bb0345","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.eururo.2007.02.034","article-title":"Testosterone and erectile function: From basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction","volume":"52","author":"Traish","year":"2007","journal-title":"Eur Urol"},{"key":"10.1002\/smrj.3_bb0350","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1743-6109.2006.00245.x","article-title":"Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence","volume":"3","author":"Traish","year":"2006","journal-title":"J Sex Med"},{"key":"10.1002\/smrj.3_bb0355","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2164\/jandrol.108.005215","article-title":"The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction","volume":"30","author":"Traish","year":"2009","journal-title":"J Androl"},{"key":"10.1002\/smrj.3_bb0360","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1743-6109.2006.00267.x","article-title":"Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: A series of case reports","volume":"3","author":"Yassin","year":"2006","journal-title":"J Sex Med"},{"key":"10.1002\/smrj.3_bb0365","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1210\/endo.136.4.7534702","article-title":"Dihydrotestosterone is the active androgen in the maintenance of nitric oxide\u2010mediated penile erection in the rat","volume":"136","author":"Lugg","year":"1995","journal-title":"Endocrinology"},{"key":"10.1002\/smrj.3_bb0370","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1210\/endo.138.9.5402","article-title":"Adrenal control of erectile function and nitric oxide synthase in the rat penis","volume":"138","author":"Penson","year":"1997","journal-title":"Endocrinology"},{"key":"10.1002\/smrj.3_bb0375","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.1464-410x.1999.00913.x","article-title":"Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum","volume":"83","author":"Park","year":"1999","journal-title":"BJU Int"},{"key":"10.1002\/smrj.3_bb0380","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1095\/biolreprod53.6.1365","article-title":"Restoration of normal adult penile erectile response in aged rats by long\u2010term treatment with androgens","volume":"53","author":"Garban","year":"1995","journal-title":"Biol Reprod"},{"key":"10.1002\/smrj.3_bb0385","first-page":"1092","article-title":"Relationship between gene expression of nitric oxide synthase and androgens in rat corpus cavernosum","volume":"113","author":"Shen","year":"2000","journal-title":"Chin Med J (Engl)"},{"key":"10.1002\/smrj.3_bb0390","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1464-410x.2000.00721.x","article-title":"Effects of androgen and ageing on gene expression of vasoactive intestinal polypeptide in rat corpus cavernosum","volume":"86","author":"Shen","year":"2000","journal-title":"BJU Int"},{"key":"10.1002\/smrj.3_bb0395","doi-asserted-by":"crossref","first-page":"14602","DOI":"10.1073\/pnas.0606544103","article-title":"Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis","volume":"103","author":"Agis\u2010Balboa","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1002\/smrj.3_bb0400","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1743-6109.2009.01309.x","article-title":"Pathways of sexual desire","volume":"6","author":"Pfaus","year":"2009","journal-title":"J Sex Med"},{"key":"10.1002\/smrj.3_bb0405","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1460-9568.2002.02084.x","article-title":"The neurosteroid allopregnanolone increases dopamine release and dopaminergic response to morphine in the rat nucleus accumbens","volume":"16","author":"Rouge\u2010Pont","year":"2002","journal-title":"Eur J Neurosci"},{"key":"10.1002\/smrj.3_bb0410","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.pnpbp.2007.09.017","article-title":"Progesterone attenuates neuroleptic\u2010induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid","volume":"32","author":"Bishnoi","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1002\/smrj.3_bb0415","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1038\/npp.2008.39","article-title":"Antipsychotic\u2010like properties of 5\u2010alpha\u2010reductase inhibitors","volume":"33","author":"Bortolato","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/smrj.3_bb0420","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0022-5347(05)68270-5","article-title":"Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men","volume":"162","author":"Overstreet","year":"1999","journal-title":"J Urol"},{"key":"10.1002\/smrj.3_bb0425","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1590\/S0041-87812004000400009","article-title":"Finasteride\u2010associated male infertility","volume":"59","author":"Glina","year":"2004","journal-title":"Rev Hosp Clin Fac Med Sao Paulo"},{"key":"10.1002\/smrj.3_bb0430","doi-asserted-by":"crossref","first-page":"849 e817","DOI":"10.1016\/j.fertnstert.2007.08.026","article-title":"Propecia\u2010induced spermatogenic failure: A report of two cases","volume":"90","author":"Liu","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1002\/smrj.3_bb0435","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/01485010701426471","article-title":"Spermatozoa and chronic treatment with finasteride: A TEM and FISH study","volume":"53","author":"Collodel","year":"2007","journal-title":"Arch Androl"},{"key":"10.1002\/smrj.3_bb0440","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.fertnstert.2010.12.061","article-title":"Finasteride\u2010induced secondary infertility associated with sperm DNA damage","volume":"95","author":"Tu","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1002\/smrj.3_bb0445","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000147852","article-title":"Immunocytochemical evidence for differential subcellular localization of 5 alpha\u2010reductase isoenzymes in human tissues","volume":"156","author":"Aumuller","year":"1996","journal-title":"Acta Anat (Basel)"},{"key":"10.1002\/smrj.3_bb0450","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1530\/REP-06-0385","article-title":"Claudin\u201011 expression and localisation is regulated by androgens in rat Sertoli cells in vitro","volume":"133","author":"Kaitu'u\u2010Lino","year":"2007","journal-title":"Reproduction"},{"key":"10.1002\/smrj.3_bb0455","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5603\/FHC.2011.0010","article-title":"DHT deficiency perturbs the integrity of the rat seminiferous epithelium by disrupting tight and adherens junctions","volume":"49","author":"Kolasa","year":"2011","journal-title":"Folia Histochem Cytobiol"},{"key":"10.1002\/smrj.3_bb0460","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0074-7696(08)60397-6","article-title":"Sertoli cell junctions: Morphological and functional correlates","volume":"94","author":"Russell","year":"1985","journal-title":"Int Rev Cytol"},{"key":"10.1002\/smrj.3_bb0465","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1677\/JME-09-0058","article-title":"Exposure of Xenopus laevis tadpoles to finasteride, an inhibitor of 5\u2010alpha reductase activity, impairs spermatogenesis and alters hypophyseal feedback mechanisms","volume":"43","author":"Urbatzka","year":"2009","journal-title":"J Mol Endocrinol"},{"key":"10.1002\/smrj.3_bb0470","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/j.1939-4640.1999.tb02503.x","article-title":"Testosterone\u2010dependent restoration of spermatogenesis in adult rats is impaired by a 5alpha\u2010reductase inhibitor","volume":"20","author":"O'Donnell","year":"1999","journal-title":"J Androl"},{"key":"10.1002\/smrj.3_bb0475","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1126\/science.186.4170.1213","article-title":"Steroid 5alpha\u2010reductase deficiency in man: An inherited form of male pseudohermaphroditism","volume":"186","author":"Imperato\u2010McGinley","year":"1974","journal-title":"Science"},{"key":"10.1002\/smrj.3_bb0480","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJM199704033361404","article-title":"Paternity by intrauterine insemination with sperm from a man with 5alpha\u2010reductase\u20102 deficiency","volume":"336","author":"Katz","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1002\/smrj.3_bb0485","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/BF00441984","article-title":"Male pseudohermaphroditism due to 5 alpha\u2010reductase deficiency in a Swedish family","volume":"147","author":"Ivarsson","year":"1988","journal-title":"Eur J Pediatr"},{"key":"10.1002\/smrj.3_bb0490","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2460\/javma.2001.218.1275","article-title":"Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy","volume":"218","author":"Sirinarumitr","year":"2001","journal-title":"J Am Vet Med Assoc"},{"key":"10.1002\/smrj.3_bb0495","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1210\/jcem.84.2.5495","article-title":"Bioavailable testosterone and depressed mood in older men: The Rancho Bernardo Study","volume":"84","author":"Barrett\u2010Connor","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"10 suppl","key":"10.1002\/smrj.3_bb0500","first-page":"31","article-title":"The aging male: Androgens, erectile dysfunction, and depression","volume":"64","author":"Seidman","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/smrj.3_bb0505","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1743-6109.2009.01504.x","article-title":"The relationship between testosterone and sexual function in depressed and healthy men","volume":"7","author":"Rizvi","year":"2010","journal-title":"J Sex Med"},{"key":"10.1002\/smrj.3_bb0510","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4088\/JCP.v66n0102","article-title":"Low testosterone levels predict incident depressive illness in older men: Effects of age and medical morbidity","volume":"66","author":"Shores","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/smrj.3_bb0515","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.psyneuen.2006.06.005","article-title":"Calculated bioavailable testosterone levels and depression in middle\u2010aged men","volume":"31","author":"McIntyre","year":"2006","journal-title":"Psychoneuroendocrinology"},{"key":"10.1002\/smrj.3_bb0520","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/archgenpsychiatry.2007.33","article-title":"Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older men","volume":"65","author":"Almeida","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/smrj.3_bb0525","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1111\/j.1743-6109.2009.01299.x","article-title":"Hypogonadism, decreased sexual desire, and long\u2010term depression in middle\u2010aged men","volume":"6","author":"Hintikka","year":"2009","journal-title":"J Sex Med"},{"key":"10.1002\/smrj.3_bb0530","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.psyneuen.2003.11.002","article-title":"One year follow\u2010up study of the association between chemical castration, sex hormones, beta\u2010amyloid, memory and depression in men","volume":"29","author":"Almeida","year":"2004","journal-title":"Psychoneuroendocrinology"},{"key":"10.1002\/smrj.3_bb0535","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1111\/j.1743-6109.2010.01859.x","article-title":"Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome","volume":"7","author":"Giltay","year":"2010","journal-title":"J Sex Med"},{"key":"10.1002\/smrj.3_bb0540","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.physbeh.2009.02.022","article-title":"Depression\u2010like behavior of aged male and female mice is ameliorated with administration of testosterone or its metabolites","volume":"97","author":"Frye","year":"2009","journal-title":"Physiol Behav"},{"key":"10.1002\/smrj.3_bb0545","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1346-8138.2002.tb00200.x","article-title":"Depression circumstantially related to the administration of finasteride for androgenetic alopecia","volume":"29","author":"Altomare","year":"2002","journal-title":"J Dermatol"},{"key":"10.1002\/smrj.3_bb0550","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6904-6-7","article-title":"Finasteride induced depression: A prospective study","volume":"6","author":"Rahimi\u2010Ardabili","year":"2006","journal-title":"BMC Clin Pharmacol"},{"key":"10.1002\/smrj.3_bb0555","first-page":"222","article-title":"Finasteride treatment and neuroactive steroid formation","volume":"110","author":"Duskova","year":"2009","journal-title":"Prague Med Rep"},{"key":"10.1002\/smrj.3_bb0560","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.pbb.2006.06.016","article-title":"Neurosteroids, neuroactive steroids, and symptoms of affective disorders","volume":"84","author":"Dubrovsky","year":"2006","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1002\/smrj.3_bb0565","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0006-8993(95)01302-4","article-title":"Effect of progesterone, testosterone and their 5 alpha\u2010reduced metabolites on GFAP gene expression in type 1 astrocytes","volume":"711","author":"Melcangi","year":"1996","journal-title":"Brain Res"},{"key":"10.1002\/smrj.3_bb0570","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.pbb.2004.04.016","article-title":"Interaction of chronic ethanol exposure and finasteride: Sex and strain differences","volume":"78","author":"Finn","year":"2004","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1002\/smrj.3_bb0575","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1073\/pnas.88.10.4553","article-title":"Stress\u2010induced elevations of gamma\u2010aminobutyric acid type A receptor\u2010active steroids in the rat brain","volume":"88","author":"Purdy","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1002\/smrj.3_bb0580","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0166-2236(99)01399-5","article-title":"Neuroactive steroids: Mechanisms of action and neuropsychopharmacological perspectives","volume":"22","author":"Rupprecht","year":"1999","journal-title":"Trends Neurosci"},{"key":"10.1002\/smrj.3_bb0585","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10517-007-0057-3","article-title":"GABA in regulation of communicative activity and sexual motivation of male mice with different psychoemotional status","volume":"143","author":"Amikishieva","year":"2007","journal-title":"Bull Exp Biol Med"},{"key":"10.1002\/smrj.3_bb0590","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.neuropharm.2007.01.022","article-title":"Steroid modulation of GABAA receptor\u2010mediated transmission in the hypothalamus: Effects on reproductive function","volume":"52","author":"Henderson","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1002\/smrj.3_bb0595","doi-asserted-by":"crossref","first-page":"8209","DOI":"10.1073\/pnas.0306631101","article-title":"Dehydroepiandrosterone and allopregnanolone protect sympathoadrenal medulla cells against apoptosis via antiapoptotic Bcl\u20102 proteins","volume":"101","author":"Charalampopoulos","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1002\/smrj.3_bb0600","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1046\/j.1471-4159.2003.01881.x","article-title":"Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum","volume":"86","author":"Ghoumari","year":"2003","journal-title":"J Neurochem"},{"key":"10.1002\/smrj.3_bb0605","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nm1073","article-title":"Niemann\u2010Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone","volume":"10","author":"Griffin","year":"2004","journal-title":"Nat Med"},{"key":"10.1002\/smrj.3_bb0610","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/jnr.20685","article-title":"Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of Niemann\u2010Pick C mice","volume":"82","author":"Ahmad","year":"2005","journal-title":"J Neurosci Res"},{"key":"10.1002\/smrj.3_bb0615","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.mehy.2009.07.010","article-title":"Do 5\u2010alpha reductase inhibitors influence the severity of brain injury in men after a stroke?","volume":"74","author":"Cohen","year":"2010","journal-title":"Med Hypotheses"},{"key":"10.1002\/smrj.3_bb0620","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.annemergmed.2005.12.011","article-title":"Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion","volume":"47","author":"Sayeed","year":"2006","journal-title":"Ann Emerg Med"},{"key":"10.1002\/smrj.3_bb0625","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1126\/science.2422758","article-title":"Steroid hormone metabolites are barbiturate\u2010like modulators of the GABA receptor","volume":"232","author":"Majewska","year":"1986","journal-title":"Science"},{"key":"10.1002\/smrj.3_bb0630","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1073\/pnas.95.6.3239","article-title":"Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine","volume":"95","author":"Uzunova","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1002\/smrj.3_bb0635","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1176\/ajp.155.7.910","article-title":"Effects of antidepressant treatment on neuroactive steroids in major depression","volume":"155","author":"Romeo","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1002\/smrj.3_bb0640","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.psyneuen.2011.08.004","article-title":"A history of depression in women is associated with an altered GABAergic neuroactive steroid profile","volume":"37","author":"Girdler","year":"2012","journal-title":"Psychoneuroendocrinology"},{"key":"10.1002\/smrj.3_bb0645","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2164\/jandrol.108.005025","article-title":"The effect of 5 alpha\u2010reductase inhibitors on erectile function","volume":"29","author":"Canguven","year":"2008","journal-title":"J Androl"},{"key":"10.1002\/smrj.3_bb0650","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3758\/CABN.1.3.287","article-title":"Inhibiting progesterone metabolism in the hippocampus of rats in behavioral estrus decreases anxiolytic behaviors and enhances exploratory and antinociceptive behaviors","volume":"1","author":"Rhodes","year":"2001","journal-title":"Cogn Affect Behav Neurosci"},{"key":"10.1002\/smrj.3_bb0655","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1006\/hbeh.2002.1763","article-title":"Changes in progesterone metabolites in the hippocampus can modulate open field and forced swim test behavior of proestrous rats","volume":"41","author":"Frye","year":"2002","journal-title":"Horm Behav"},{"key":"10.1002\/smrj.3_bb0660","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00213-005-0100-x","article-title":"Inhibiting 5alpha\u2010reductase in the amygdala attenuates antianxiety and antidepressive behavior of naturally receptive and hormone\u2010primed ovariectomized rats","volume":"186","author":"Walf","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1002\/smrj.3_bb0665","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.pbb.2004.03.024","article-title":"Hippocampal 3alpha,5alpha\u2010THP may alter depressive behavior of pregnant and lactating rats","volume":"78","author":"Frye","year":"2004","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1002\/smrj.3_bb0670","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1523\/JNEUROSCI.20-05-01982.2000","article-title":"Neuroactive steroid 3alpha\u2010hydroxy\u20105alpha\u2010pregnan\u201020\u2010one modulates electrophysiological and behavioral actions of ethanol","volume":"20","author":"VanDoren","year":"2000","journal-title":"J Neurosci"},{"key":"10.1002\/smrj.3_bb0675","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-0030-1249095","article-title":"Finasteride treatment inhibits adult hippocampal neurogenesis in male mice","volume":"43","author":"Romer","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/smrj.3_bb0680","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/dneu.20457","article-title":"Testosterone and dihydrotestosterone, but not estradiol, enhance survival of new hippocampal neurons in adult male rats","volume":"67","author":"Spritzer","year":"2007","journal-title":"Dev Neurobiol"},{"key":"10.1002\/smrj.3_bb0685","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1940-6207.CAPR-08-0092","article-title":"Finasteride does not increase the risk of high\u2010grade prostate cancer: A bias\u2010adjusted modeling approach","volume":"1","author":"Redman","year":"2008","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1002\/smrj.3_bb0690","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1529-8019.2010.01358.x","article-title":"Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: Fact or fiction?","volume":"23","author":"Lynn","year":"2010","journal-title":"Dermatol Ther"},{"key":"10.1002\/smrj.3_bb0695","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.ejca.2005.06.010","article-title":"The finasteride Prostate Cancer Prevention Trial (PCPT)\u2013what have we learned?","volume":"41","author":"Mellon","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1002\/smrj.3_bb0700","first-page":"22","article-title":"Histopathological effects of androgen deprivation in prostatic cancer","volume":"14","author":"Civantos","year":"1996","journal-title":"Semin Urol Oncol"},{"key":"10.1002\/smrj.3_bb0705","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3816\/CGC.2004.n.004","article-title":"Does finasteride alter the pathology of the prostate and cancer grading?","volume":"2","author":"Bostwick","year":"2004","journal-title":"Clin Prostate Cancer"},{"key":"10.1002\/smrj.3_bb0710","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0090-4295(98)00579-2","article-title":"Does long\u2010term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long\u2010Term Efficacy and Safety Study","volume":"53","author":"Yang","year":"1999","journal-title":"Urology"},{"key":"10.1002\/smrj.3_bb0715","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/jnci\/djm117","article-title":"Finasteride and high\u2010grade prostate cancer in the Prostate Cancer Prevention Trial","volume":"99","author":"Lucia","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1002\/smrj.3_bb0720","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/jnci\/djj307","article-title":"Effect of finasteride on the sensitivity of PSA for detecting prostate cancer","volume":"98","author":"Thompson","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1002\/smrj.3_bb0725","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2164\/jandrol.107.002931","article-title":"Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone","volume":"28","author":"Vaughan","year":"2007","journal-title":"J Androl"},{"key":"10.1002\/smrj.3_bb0730","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/oxfordjournals.aje.a116360","article-title":"Breast cancer in men: Risk factors with hormonal implications","volume":"135","author":"Thomas","year":"1992","journal-title":"Am J Epidemiol"},{"key":"10.1002\/smrj.3_bb0735","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0302-2838(02)00273-7","article-title":"Study of the association between ischemic heart disease and use of alpha\u2010blockers and finasteride indicated for the treatment of benign prostatic hyperplasia","volume":"42","author":"Souverein","year":"2002","journal-title":"Eur Urol"},{"key":"10.1002\/smrj.3_bb0740","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4149\/endo_2010_01_3","article-title":"Changes of metabolic profile in men treated for androgenetic alopecia with 1\u2009mg finasteride","volume":"44","author":"Duskova","year":"2010","journal-title":"Endocr Regul"},{"key":"10.1002\/smrj.3_bb0745","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0090-4295(03)00661-7","article-title":"Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia","volume":"62","author":"Roehrborn","year":"2003","journal-title":"Urology"},{"key":"10.1002\/smrj.3_bb0750","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1210\/en.2009-1268","article-title":"Dihydrotestosterone suppresses foam cell formation and attenuates atherosclerosis development","volume":"151","author":"Qiu","year":"2010","journal-title":"Endocrinology"},{"key":"10.1002\/smrj.3_bb0755","unstructured":"Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/InformationbyDrugClass\/ucm299754.htm (accessed March 18, 2013)."},{"key":"10.1002\/smrj.3_bb0760","unstructured":"Available at: http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm258529.htm (accessed March 18, 2013)."},{"key":"10.1002\/smrj.3_bb0765","unstructured":"Available at: http:\/\/www.smsna.org\/about\/position.asp (accessed March 18, 2013)."}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052115300615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052115300615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T17:20:07Z","timestamp":1715275207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2050052115300615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":152,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S2050052115300615"],"URL":"https:\/\/doi.org\/10.1002\/smrj.3","relation":{},"ISSN":["2050-0521"],"issn-type":[{"value":"2050-0521","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}